Fulvestrant

Name: Fulvestrant
SKU: F8147
Availability: InStock

Product ID F8147

Cas No. 129453-61-8

Purity ≥98%

Product Unit Size	Cost	Quantity		Stock

Bulk Quote

Quicklinks

Description
Product Info
Shipping and Storage
Downloads
References

Description

Fulvestrant is an anti-endocrine compound that exhibits anticancer chemotherapeutic benefit in the treatment of estrogen receptor (ER)-positive breast cancer. Fulvestrant causes degradation of ERs and downregulates ER expression, inhibiting cell growth. Fulvestrant also upregulates expression of UDP glucoronosyltransferase 1A4 (UGT1A4) in cancer cells. Additionally, fulvestrant exhibits some anti-hyperlipidemic benefit in clinical settings, as patients receiving it as a chemotherapeutic also exhibited lower serum levels of total cholesterol and LDL.

Product Info

Cas No.	129453-61-8
Purity	≥98%
Formula	C₃₂H₄₇F₅O₃S
Formula Wt.	606.77
Chemical Name	(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
IUPAC Name	(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5, 5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16, 17-decahydrocyclopenta[a]phenanthrene-3,17-diol
Synonym	Faslodex
Solubility	Soluble in ethanol (>200 mg/mL), DMSO (>20 mg/mL). Insoluble in water. DMF 20 mg/mL, chloroform.
Appearance	White to off white powder

Shipping and Storage

Store Temp	Ambient
Ship Temp	Ambient

Downloads

MSDS	F8147 MSDS PDF
Info Sheet	F8147 Info Sheet PDF

References

Edavana VK, Penney RB, Yao-Borengasser A, et al. Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism. Springerplus. 2013 Nov 20;2:620. PMID: 24298433.

Krell J, Januszewski A, Yan K, et al. Role of fulvestrant in the management of postmenopausal breast cancer. Expert Rev Anticancer Ther. 2011 Nov;11(11):1641-52. PMID: 22050013.

Scott SM, Brown M, Come SE. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer. Expert Opin Drug Saf. 2011 Sep;10(5):819-26. PMID: 21699443

Camerini A, Rondini M, Garrone O, et al. Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients. Cancer Biol Ther. 2009 Aug;8(15):1450-5. PMID: 19556864.

Custom Order

Name*
First Last
Company/Institution
Email*
Enter Email Confirm Email
Product ID
Product Name
Unit Size
Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
Unit Label
Quantity
Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
Comments
Phone
This field is for validation purposes and should be left unchanged.

Fulvestrant

Quicklinks

Description

Product Info

Shipping and Storage

Downloads

References

Custom Order

Related Products

GDC-0994

γ-Tocopherol

D-Seco Paclitaxel

CV-65

Dexamethasone

Tetrodotoxin Citrate

Nimodipine

Thienylhexyl Isothiocyanate

Halometasone

Ginsenoside Rh1

Primaquine Phosphate

Sanguinarine

Minoxidil

D-Limonene

Ceftazidime Hydrate

Kahweol Acetate

Calcitonin Gene Related Peptide II, rat

2′,7-Bisacetyltaxol

S-(−)-Sulpiride

2-Epi-16-deoxysarcophine

Footer